LFMD News

LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)

Kuehn Law Encourages Investors of LifeMD, Inc. to Contact Law Firm

LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.

LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Contact Levi & Korsinsky by October 25, 2025 to Join Class Action Against LifeMD, Inc. (LFMD)

LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026

LifeMD Reports Third Quarter 2025 Results

LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk